The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2023 | Why are patients from more deprived backgrounds underrepresented in myeloma trials?
Amrutha Sridhar, MBBS, University College London Hospitals, London, UK, comments on possible factors that lead to poorer participation of patients from a lower socioeconomic background in multiple myeloma clinical trials. Factors that determined social deprivation, such as less education and access to healthcare, may contribute to the underrepresentation of this patient population in trials. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
